Lara A. Kahale

Lara A. Kahale

Auto-generated profile, based on publicly available information

Lara A. Kahale

Cochrane Central Executive, Cochrane, London, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
GLGary H. Lyman
Gary H. Lyman
MCMarc Carrier
Marc Carrier
CACihan Ay
Cihan Ay
MNMarcello Di Nisio
Marcello Di Nisio
LHLisa K. Hicks
Lisa K. Hicks
PAPablo Alonso
Pablo Alonso
Background: Venous thromboembolism (VTE) is a common complication among patients with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and mortality.Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of VTE in patients with cancer.Methods: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The guideline development process was supported by updated or new systematic evidence reviews. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess evidence and make recommendations.Results: Recommendations address mechanical and pharmacological prophylaxis in hospitalized medical patients with cancer, those undergoing a surgical procedure, and ambulatory patients receiving cancer chemotherapy. The recommendations also address the use of anticoagulation for the initial, short-term, and long-term treatment of VTE in patients with cancer.Conclusions: Strong recommendations include not using thromboprophylaxis in ambulatory patients receiving cancer chemotherapy at low risk of VTE and to use low-molecular-weight heparin (LMWH) for initial treatment of VTE in patients with cancer. Conditional recommendations include using thromboprophylaxis in hospitalized medical patients with cancer, LMWH or fondaparinux for surgical patients with cancer, LMWH or direct oral anticoagulants (DOAC) in ambulatory patients with cancer receiving systemic therapy at high risk of VTE and LMWH or DOAC for initial treatment of VTE, DOAC for the short-term treatment of VTE, and LMWH or DOAC for the long-term treatment of VTE in patients with cancer.

1 November 2017 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
JEJulian H. Elliott
Julian H. Elliott
ASAnneliese Synnot
Anneliese Synnot
TTTari Turner
Tari Turner
MSMark Simmonds
Mark Simmonds
EAElie Akl
Elie Akl
LPLeslea Pearson
Leslea Pearson

1 November 2017 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
JTJames Thomas
James Thomas
ANAnna Noel-Storr
Anna Noel-Storr
IMIain Marshall
Iain Marshall
BWByron Wallace
Byron Wallace
SMSteven McDonald
Steven McDonald
LPLeslea Pearson
Leslea Pearson
New approaches to evidence synthesis, which use human effort and machine automation in mutually reinforcing ways, can enhance the feasibility and sustainability of living systematic reviews. Human effort is a scarce and valuable resource, required when automation is impossible or undesirable, and includes contributions from online communities ("crowds") as well as more conventional contributions from review authors and information specialists. Automation can assist with some systematic review tasks, including searching, eligibility assessment, identification and retrieval of full-text reports, extraction of data, and risk of bias assessment. Workflows can be developed in which human effort and machine automation can each enable the other to operate in more effective and efficient ways, offering substantial enhancement to the productivity of systematic reviews. This paper describes and discusses the potential-and limitations-of new ways of undertaking specific tasks in living systematic reviews, identifying areas where these human/machine "technologies" are already in use, and where further research and development is needed. While the context is living systematic reviews, many of these enabling technologies apply equally to standard approaches to systematic reviewing.

1 November 2017 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
EAElie Akl
Elie Akl
JMJoerg J. Meerpohl
Joerg J. Meerpohl
JEJulian Elliott
Julian Elliott
LKLara A. Kahale
Lara A. Kahale
HSHolger J. Schünemann
Holger J. Schünemann
LPLeslea Pearson
Leslea Pearson

13 April 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HBHneine Brax
Hneine Brax
RFRacha Fadlallah
Racha Fadlallah
LALina Al-Khaled
Lina Al-Khaled
LKLara A. Kahale
Lara A. Kahale
HNHala Nas
Hala Nas
EAElie Akl
Elie Akl
Pharmaceutical company representatives likely influence the prescribing habits and professional behaviors of physicians. The objective of this study was to systematically review the association between physicians’ interactions with pharmaceutical companies and their clinical practices. We used the standard systematic review methodology. Observational and experimental study designs examining any type of targeted interaction between practicing physicians and pharmaceutical companies were eligible. The search strategy included a search of MEDLINE and EMBASE databases up to July 2016. Two reviewers selected studies, abstracted data, and assessed risk of bias in duplicate and independently. We assessed the quality of evidence using the GRADE approach. Twenty articles reporting on 19 studies met our inclusion criteria. All of these studies were conducted in high-income countries and examined different types of interactions, including detailing, industry-funded continuing medical education, and receiving free gifts. While all included studies assessed prescribing behaviors, four studies also assessed financial outcomes, one assessed physicians’ knowledge, and one assessed their beliefs. None of the studies assessed clinical outcomes. Out of the 19 studies, 15 found a consistent association between interactions promoting a medication, and inappropriately increased prescribing rates, lower prescribing quality, and/or increased prescribing costs. The remaining four studies found both associations and lack of significant associations for the different types of exposures and drugs examined in the studies. A meta-analysis of six of these studies found a statistically significant association between exposure and physicians’ prescribing behaviors (OR = 2.52; 95% CI 1.82–3.50). The quality of evidence was downgraded to moderate for risk of bias and inconsistency. Sensitivity analysis excluding studies at high risk of bias did not substantially change these results. A subgroup analysis did not find a difference by type of exposure. There is moderate quality evidence that physicians’ interactions with pharmaceutical companies are associated with their prescribing patterns and quality.

1 July 2017 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
GGGordon H. Guyatt
Gordon H. Guyatt
SEShanil Ebrahim
Shanil Ebrahim
PAPablo Alonso
Pablo Alonso
BJBradley C. Johnston
Bradley C. Johnston
Alexander MathioudakisAlexander Mathioudakis
Alexander Mathioudakis
EAElie Akl
Elie Akl